Patents by Inventor Brian Walter

Brian Walter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12383601
    Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: August 12, 2025
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
  • Publication number: 20250231745
    Abstract: Systems, and methods are described for a ML model generating sections of code based on inputs. The systems of generating code may receive inputs. The first input may be a description of problems for solving and a specification of an output. The second input may be variables. The third input may be data categories associated with the variables and the output. The fourth input may be responses to prompts. The prompts may be generated by a ML model based on association between the first, second, and third inputs. Boilerplate sections of code may be determined by the ML model. Missing portions of code are determined. Missing portions of code may be associated with core sections of code. The ML model may utilize the inputs to generate code to fill in missing portions of code. Generated code including missing portions and sections of generated code are provided to a user interface.
    Type: Application
    Filed: December 23, 2024
    Publication date: July 17, 2025
    Inventors: William Moten, Hardik Punjabi, Zhiyu Liu, Nehal Sheth, Shreyas Shrivastava, Vasanth Chandrasekaran, Carissa Ann Melasippo, Nathalie Saade, Deepak Agrawal, Jordan David Kendall, Brian Walters
  • Publication number: 20250215081
    Abstract: The present disclosure provides combinations of anti-CD19 agents and B cell targeting agents and methods of treating subjects having B cell malignancies with combinations of anti-CD19 agents and a B cell targeting agents.
    Type: Application
    Filed: November 4, 2021
    Publication date: July 3, 2025
    Inventors: Kimberly Marie AARDALEN, Regis CEBE, Dattananda CHELUR, Glenn DRANOFF, Brian Walter GRANDA, Nadia HASSOUNAH, Connie HONG, Sunyoung JANG, Haihui LU, Amy RAYO, Darko SKEGRO, Janghee WOO
  • Publication number: 20250206746
    Abstract: 4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).
    Type: Application
    Filed: December 20, 2024
    Publication date: June 26, 2025
    Inventors: Gopi Kumar Mittapalli, Chi Ching Mak, Ramkrishna Reddy Vakiti, Brian Joseph Hofilena, Brian Walter Eastman, Lewis Daniel Turner
  • Publication number: 20250171466
    Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).
    Type: Application
    Filed: August 15, 2024
    Publication date: May 29, 2025
    Inventors: Gopi Kumar Mittapalli, Sunil Kumar KC, Chi Ching Mak, Brian Joseph Hofilena, Lewis Daniel Turner, Brian Walter Eastman, Ramkrishna Reddy Vakiti, Joseph Timothy Marakovits
  • Patent number: 12314045
    Abstract: Some implementations of the disclosure are directed to a method, comprising: receiving tapped data that was tapped from a controller of an industrial control system (ICS) while the controller executed first control code to control ICS devices of the ICS, the tapped data used during execution of the first control code, and the tapped data comprising input data obtained from one or more input components of the controller communicatively coupled to the ICS devices, or output data obtained from one or more output components of the controller communicatively coupled to the ICS devices; and after receiving the tapped data, executing, using at least the tapped data, second control code that provides an emulation of the controller, the emulation comprising running, using at least the tapped data, a process of the first control code at a faster rate than it is run by the controller executing the first control code.
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: May 27, 2025
    Assignee: Disney Enterprises, Inc.
    Inventors: Justin Brock, Brian Walters, Nicholas Stantzos, Christopher Hofer, Mario Scarabino, Michael Tschanz
  • Publication number: 20250129104
    Abstract: 7H-Pyrrolo[2,3-d]pyrimidine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 7H-pyrrolo[2,3-d]pyrimidine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).
    Type: Application
    Filed: December 9, 2024
    Publication date: April 24, 2025
    Inventors: Gopi Kumar Mittapalli, Sunil Kumar KC, Chi Ching Mak, Brian Joseph Hofilena, Chandramouli Chiruta, Ramkrishna Reddy Vakiti, Brian Walter Eastman, Joseph Timothy Marakovits, Lewis Daniel Turner
  • Patent number: 12281097
    Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: April 22, 2025
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
  • Patent number: 12271375
    Abstract: Executing a query in a disaggregated cluster. A query is received at the disaggregated cluster. A query graph is created based on the query that identifies a hierarchy of vertices, where each vertex is associated with a set of data responsive to at least a portion of the query. The compute nodes process the query graph by first identifying a minimum set of tables, files, and objects stored on the storage nodes required to retrieve data that satisfy the query. Next, the compute nodes selectively assign the identified tables, files, and objects to a leaf vertex of the query graph to optimize retrieving data from the storage nodes. Thereafter, the compute nodes process the retrieved data sets associated with each vertex using separate threads of execution for each vertex of the query graph such that leaf vertices are performed in parallel. The compute nodes then provide a result set.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: April 8, 2025
    Assignee: Wind Jammer Technologies, LLC
    Inventors: Brian Walter O'Krafka, John Richard Busch, Manavalan Krishnan, Kai Rothauge
  • Publication number: 20250000973
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: August 19, 2022
    Publication date: January 2, 2025
    Inventors: Michael Bardroff, Regis Cebe, Brian Walter Granda, Shyamali Jayashankar, Sandeep Tharian Koshy, Sandra Miller, Andrew Patrick Price, Amy Rayo, Darko Skegro, Louise Mary Treanor, Jennifer Yang
  • Patent number: 12167547
    Abstract: Examples are disclosed that relate to display devices and mounting brackets for securing a bezel to a display device. In one example, a display device comprises a display unit and a bezel comprising at least one pocket. The display device comprises a mounting bracket comprising a display unit attachment portion affixed to the display unit and at least one tongue that extends at least partially into the at least one pocket. Adhesive binds the at least one tongue to at least one surface of the at least one pocket, thereby coupling the bezel to the display unit via the mounting bracket.
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: December 10, 2024
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Joseph Juseop Park, John Charles Meyer, Bruce James Sandmeyer, Brian Walter Aznoe, Dallas Jamison Cutler, James David Wahl
  • Patent number: 12134625
    Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).
    Type: Grant
    Filed: October 12, 2022
    Date of Patent: November 5, 2024
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: Gopi Kumar Mittapalli, Sunil Kumar K C, Chi Ching Mak, Brian Joseph Hofilena, Lewis Daniel Turner, Brian Walter Eastman, Ramkrishna Reddy Vakiti, Joseph Timothy Marakovits
  • Patent number: 12120222
    Abstract: A computer-implemented method for providing a system-specific secret to a computing system having a plurality of computing components is disclosed. The method includes storing permanently a component-specific import key as part of a computing component and storing the component-specific import key in a manufacturing-side storage system. Upon a request for the system-specific secret for a computing system, the method includes identifying the computing component comprised in the computing system, retrieving a record relating to the identified computing component, determining the system-specific secret protected by a hardware security module and determining a system-specific auxiliary key. Furthermore, the method includes encrypting the system-specific auxiliary key with the retrieved component-specific import key, thereby creating a auxiliary key bundle, encrypting the system-specific secret and storing the auxiliary key bundle and a system record in a storage medium of the computing system.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: October 15, 2024
    Assignee: International Business Machines Corporation
    Inventors: Reinhard Theodor Buendgen, Brian Walter Stocker, Nicolas Maeding, Jonathan D. Bradbury
  • Publication number: 20240252538
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Application
    Filed: December 5, 2023
    Publication date: August 1, 2024
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • Publication number: 20240199649
    Abstract: 4-Aminopyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-aminopyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, and osteoarthritis).
    Type: Application
    Filed: November 3, 2023
    Publication date: June 20, 2024
    Inventors: Gopi Kumar Mittapalli, Chi Ching Mak, Lewis Daniel Turner, Ramkrishna Reddy Vakiti, Brian Walter Eastman, Brian Joseph Hofilena
  • Publication number: 20240025993
    Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 25, 2024
    Inventors: Regis CEBE, Dattananda CHELUR, Brian Walter GRANDA, Connie WONG, Sunyoung JANG, Haihui LU, Amy RAYO, Darko SKEGRO
  • Patent number: 11872249
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 16, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Patricia Pinto Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
  • Publication number: 20240002509
    Abstract: The present invention relates to antibodies comprising Fc variants and their uses. The Fc variants exhibit reduced or undetectable binding to Fc receptors, and reduced or undetectable effector functions. These variants are beneficial for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector functions induced by antibodies.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 4, 2024
    Inventors: Brian Walter GRANDA, Darko SKEGRO
  • Publication number: 20240002391
    Abstract: 4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).
    Type: Application
    Filed: June 23, 2023
    Publication date: January 4, 2024
    Inventors: Gopi Kumar Mittapalli, Chi Ching Mak, Lewis Daniel Turner, Brian Joseph Hofilena, Ramkrishna Reddy Vakiti, Brian Walter Eastman, David Mark Wallace
  • Publication number: 20230312605
    Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer’s disease, diabetes, viral infections, and osteoarthritis).
    Type: Application
    Filed: October 12, 2022
    Publication date: October 5, 2023
    Inventors: Gopi Kumar Mittapalli, Sunil Kumar KC, Chi Ching Mak, Brian Joseph Hofilena, Lewis Daniel Turner, Brian Walter Eastman, Ramkrishna Reddy Vakiti, Joseph Timothy Marakovits